Evidence map›Paper›PMID 27509068›Full record

ReviewACS combinatorial science2016

Cellular Delivery of RNA Nanoparticles.

Lorena Parlea, Anu Puri, Wojciech Kasprzak, Eckart Bindewald, Paul Zakrevsky, Emily Satterwhite, Kenya Joseph, Kirill A Afonin, Bruce A Shapiro

Abstract readReview
In one paragraph

Review in ACS combinatorial science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Using aptamers for targeted delivery of RNA therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs).Nanomedicine : nanotechnology, biology, and medicine · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lorena ParleaGene Regulation and Chromosome Biology Laboratory, National Cancer Institute , Frederick, Maryland 21702, United States.
Anu PuriGene Regulation and Chromosome Biology Laboratory, National Cancer Institute , Frederick, Maryland 21702, United States.
Wojciech KasprzakBasic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research , Frederick, Maryland 21702, United States.
Eckart BindewaldBasic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research , Frederick, Maryland 21702, United States.
Paul ZakrevskyGene Regulation and Chromosome Biology Laboratory, National Cancer Institute , Frederick, Maryland 21702, United States.
Emily SatterwhiteDepartment of Chemistry, University of North Carolina at Charlotte , Charlotte, North Carolina 28223, United States.
Kenya JosephDepartment of Chemistry, University of North Carolina at Charlotte , Charlotte, North Carolina 28223, United States.
Kirill A AfoninDepartment of Chemistry, University of North Carolina at Charlotte , Charlotte, North Carolina 28223, United States.
Bruce A ShapiroGene Regulation and Chromosome Biology Laboratory, National Cancer Institute , Frederick, Maryland 21702, United States.

Funding

Computational RNA NanodesignZIABC011061 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAPIRO, BRUCE · 2009 to 2021
$12.3M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011061NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

RNA nanostructures can be programmed to exhibit defined sizes, shapes and stoichiometries from naturally occurring or de novo designed RNA motifs. These constructs can be used as scaffolds to attach functional moieties, such as ligand binding motifs or gene expression regulators, for nanobiology applications. This review is focused on four areas of importance to RNA nanotechnology: the types of RNAs of particular interest for nanobiology, the assembly of RNA nanoconstructs, the challenges of cellular delivery of RNAs in vivo, and the delivery carriers that aid in the matter. The available strategies for the design of nucleic acid nanostructures, as well as for formulation of their carriers, make RNA nanotechnology an important tool in both basic research and applied biomedical science.

Indexed as

AnimalsAptamers, NucleotideChemistry, PharmaceuticalComputational BiologyDrug Delivery SystemsDrug DesignDrug LiberationGenetic TherapyGenetic VectorsHumansMolecular Targeted TherapyNanoparticlesNanotechnologyRNARNA InterferenceRNA SplicingAptamers, NucleotideRNAdeliverynanoconstructRNARNA nanoparticleself-assemblytherapeutics

Identifiers

PMID27509068
PMCPMC6345529

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.